This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Neogen (NEOG) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Neogen (NEOG) give insight into how the company performed in the quarter ended May 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Neogen (NEOG) Q4 Earnings Lag Estimates
by Zacks Equity Research
Neogen (NEOG) delivered earnings and revenue surprises of -37.50% and +1.90%, respectively, for the quarter ended May 2025. Do the numbers hold clues to what lies ahead for the stock?
InMode (INMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
InMode (INMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Neogen (NEOG) Q4 Earnings Expected to Decline
by Zacks Equity Research
Neogen (NEOG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ResMed (RMD) Up 4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
ResMed (RMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Neogen Stock Gains Following Strategic Alliance With Syngenta
by Zacks Equity Research
NEOG inks a new strategic licensing and supply agreement with Syngenta to market and sell the latter's Talon-G and Talon Weatherblok XT rodenticides in the United States and Canada.
Abbott (ABT) Up 1.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Neogen (NEOG) Up 6.4% Since Last Earnings Report?
by Zacks Equity Research
Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Company News for Apr 10, 2025
by Zacks Equity Research
Companies in The News Are: DAL,AMPL,NEOG,GM
Neogen Stock Tumbles on Q3 Earnings & Sales Miss, Margins Contract
by Zacks Equity Research
NEOG posts lower-than-expected earnings and revenues for the third quarter of fiscal 2025.
Neogen (NEOG) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Neogen (NEOG) give a sense of how the business performed in the quarter ended February 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Neogen (NEOG) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Neogen (NEOG) delivered earnings and revenue surprises of -23.08% and 0.92%, respectively, for the quarter ended February 2025. Do the numbers hold clues to what lies ahead for the stock?
Seeking Clues to Neogen (NEOG) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Neogen (NEOG) for the quarter ended February 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Should You Bet on PAHC Stock at a Discounted P/E of 10.41X?
by Moumi Mondal
PAHC's solid MFA franchise, now bolstered by Zoetis' portfolio, makes it a solid investment case. A well-established foothold in key regions is also a factor.
Cresco Labs Inc. (CRLBF) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cresco Labs Inc. (CRLBF) delivered earnings and revenue surprises of 0% and 2.26%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
NEOG Stock Gains Following the Launch of Its New MDA2QSAL96 Kit
by Zacks Equity Research
Neogen launches the new Molecular Detection Assay 2 - Quantitative Salmonella (MDA2QSAL96) to deliver consistency and sensitivity with an easy-to-use workflow that saves time and resources.
NEOG Prelim Q2 Earnings Meet, '25 Sales View Down, Stock Falls
by Zacks Equity Research
NEOG's Food Safety business witnesses a slight year-over-year decrease in revenues for the second quarter of fiscal 2025.
Neogen (NEOG) Q2 Earnings Match Estimates
by Zacks Equity Research
Neogen (NEOG) delivered earnings and revenue surprises of 0% and 2.16%, respectively, for the quarter ended November 2024. Do the numbers hold clues to what lies ahead for the stock?
Exploring Analyst Estimates for Neogen (NEOG) Q2 Earnings, Beyond Revenue and EPS
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Neogen (NEOG), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended November 2024.
Macroeconomic Woes, FX Headwind Drag NEOG Stock Down
by Zacks Equity Research
NEOG faces intense competition due to the development of new technologies by competitors, which could affect the marketability and profitability of its products.
NEOG Stock Gains From New Addition to the Petrifilm Product Line
by Zacks Equity Research
Neogen expands the Petrifilm product line with the introduction of Petrifilm Bacillus cereus Count Plate.
Quipt Home Medical Corp. (QIPT) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Quipt Home Medical (QIPT) delivered earnings and revenue surprises of -800% and 6.72%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Competitive Pressure, Macroeconomic Woes Weigh on NEOG Stock
by Zacks Equity Research
NEOG faces intense competition resulting from competitors' development of new technologies, which could affect the marketability and profitability of its products.
Neogen Q1 Earnings Miss Estimates, Margins Crash
by Zacks Equity Research
NEOG's Food Safety and Animal Safety businesses witness a year-over-year decrease in revenues in the first quarter of fiscal 2025.
Company News for Oct 11, 2024
by Zacks Equity Research
Companies in The News Are: DAL,DPZ,NEOG,TXG